INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect

PMID: 20420527
Journal: Expert opinion on biological therapy (volume: 10, issue: 6, Expert Opin Biol Ther 2010 Jun;10(6):983-91)
Published: 2010-06-01

Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI


IMPORTANCE OF THE FIELD: Novel approaches are needed for patients with small cell lung cancer (SCLC), as response after relapse is poor with standard therapies. p53 gene mutations often occur, resulting in tumoral protein overexpression and allowing for their recognition by p53-specific cytotoxic T cells.

AREAS COVERED IN THIS REVIEW: We describe the characteristics and manufacturing of INGN-225, a p53-modified adenovirus-tranduced dendritic cell vaccine, and review available data, to understand INGN-225’s role in SCLC treatment. We discuss our pre-clinical, early Phase I/II, and ongoing randomized Phase II studies.

WHAT THE READER WILL GAIN: INGN-225 was well tolerated (all toxicities

TAKE HOME MESSAGE: INGN-225 is safe, induces a significant immune response, and appears to sensitize SCLC to subsequent chemotherapy. Improvements in immune response induction and understanding the chemotherapy-immunotherapy synergism will determine INGN-225’s future role as an anticancer therapy.